SLC13A5 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
SLC13A5 Deficiency Market Outlook
Thelansis’s “SLC13A5 Deficiency Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential SLC13A5 Deficiency treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
SLC13A5
Deficiency Overview
SLC13A5
deficiency is a rare autosomal recessive disorder caused by mutations in the
sodium-coupled citrate transporter gene SLC13A5. It is characterized by
infantile seizures and neurodevelopmental delays. Patients with SLC13A5 citrate
transporter disorder are initially identified by the multiple types of seizures
that begin within the first week of life. This rare disease is due to changes
(mutations) in the SLC13A5 gene (solute carrier family 13, member 5). Seizures
begin within a few days of birth, which are often refractory to medications and
most patients remain on anti-seizure medications throughout life. Additional
symptoms include limited ability to speak, slow motor development including
problems standing or walking independently, as well as abnormalities in tooth
enamel. Problems with tone are also reported with chronic low tone but also
periodic episodes of body stiffening and post stiffening weakness. Siblings
with the same genetic mutation show differences in the severity of symptoms.
Variations include the type and frequency of seizures as well as the time
course of developmental milestones.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment